Enveric Biosciences Advances Mental Health Treatment with Neuroplasticity Enhancing Drug

From its EVM301 portfolio, Enveric Biosciences has chosen EB-003 as its principal therapeutic prospect for managing mental health conditions. 

The treatment aids in enhancing neuroplasticity without inducing hallucinatory effects. 

Early-stage research on the medication is expected to start at the beginning of the upcoming year, and the company is looking into filing a request for their experimental drug for a phase I clinical study. The drug is aimed at treating anxiety and depression.  

Out of all the prospects, three drug treatments were selected, with EB-003 distinguishing itself for its extensive features. 

Joeseph Tucker, the leading executive of Enveric, commented, “Importantly, moving EB-003 into our development pipeline marks a transformative step for Enveric as we complete our period as a discovery phase company and fully transition to the next phase as a drug development company.” 

Tucker went on to add, “With EB-003, we have identified a novel, neuroplastogenic molecule that exhibits several key properties that align with favourable tolerability and efficacy in relevant animal models.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.